Inventor · disambiguated record
Michael L. Gosselin
Also filed as: GOSSELIN MICHAEL · GOSSELIN MICHAEL L
14 granted patents·3 pending applications·321 citations·filing 1992–2024
93Inventor score
Files withBRISTOL MYERS SQUIBB CO12T CELL SCIENCES INC2AVANT IMMUNOTHERAPEUTICS INC1GOSSELIN MICHAEL L1PRAECIS PHARM INC1
Top patents by PatentIndex Score
17 records- 0194US9540424B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 10, 2017·27 cites·19 claims
- 0294US8969289B2Serum albumin binding moleculesGOSSELIN MICHAEL L·Filed 2011·Granted Mar 3, 2015·45 cites·33 claims
- 0393US10221438B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 5, 2019·12 cites·16 claims
- 0492US11434275B2Fast-off rate serum albumin binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Sep 6, 2022·3 cites·18 claims
- 0592US5456909AGlycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivoT CELL SCIENCES INC·Filed 1992·Granted Oct 10, 1995·92 cites·16 claims
- 0691US10934572B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 2, 2021·4 cites·16 claims
- 0790US10442851B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 15, 2019·5 cites·12 claims
- 0888US11919954B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·1 cites·28 claims
- 0987US10766946B2Fast-off rate serum albumin binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 8, 2020·4 cites·11 claims
- 1087US5858969ATherapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)T CELL SCIENCES INC·Filed 1995·Granted Jan 12, 1999·72 cites·16 claims
- 1186US11203630B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 21, 2021·2 cites·9 claims
- 1284US11155618B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 26, 2021·1 cites·35 claims
- 1384US6057131APreparation and use of sialylated glycoforms of soluble complement receptor 1 (CR1)AVANT IMMUNOTHERAPEUTICS INC·Filed 1998·Granted May 2, 2000·53 cites·28 claims
- 1481US2024228615A1Anti-trem-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1574US11952420B2Nucleic acids encoding anti-TREM-1 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Apr 9, 2024·0 cites·25 claims
- 1672US2023145413A1Fast-off rate serum albumin binding fibronectin type iii domainsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1741US2002133001A1Therapeutic agents and methods of use thereof for treating an amyloidogenic diseasePRAECIS PHARM INC·Filed 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael L. Gosselin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →